youtube_live
Q3 2026 earnings • released • EPS miss -84.80% • Revenue miss -17.53%
See resultschevron_right
IBRX:NASDAQ
Immunitybio Inc
$6.02
arrow_downward
-0.82%(-0.050) 1D
$6.03
arrow_upward
+0.17% (+0.010)bedtimeAfter hours
Closed: Nov 13, 4:00:01 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for IBRX...
Open
$6.10
High
$6.17
Low
$5.83
Mkt. cap
6.40B
Avg. vol.
15.13M
Volume
13.33M
52-wk high
$12.43
52-wk low
$1.95
EPS
-$1.07
Beta
0.17
Shares outstanding
1.06B
No. of employees
688
Open
$6.10
High
$6.17
Low
$5.83
Mkt. cap
6.40B
Avg. vol.
15.13M
Volume
13.33M
52-wk high
$12.43
52-wk low
$1.95
EPS
-$1.07
Beta
0.17
Shares outstanding
1.06B
No. of employees
688
News stories
From web sources and news partners
Stocktwits
·
12 hours ago
IBRX Stock In Focus As Institutional Investor Boosts Stake By Over 15% In Q3 — All Eyes On ImmunityBio’s London Conferences Next Week
Stocktwits
·
1 day ago
IBRX Stock Eyes Best Year Ever: Founder Teases 12 Months Of ‘Stealth’ NantWorks Reveals — Cancer Tech, AI Chips And Satellites
Yahoo Finance
·
1 day ago
ImmunityBio (IBRX) is Declining For 4 Days Now. What’s Triggering the Selloff?
Stocks Down Under
·
1 day ago
ImmunityBio (NDQ:IBRX): The Next Keytruda Or The Next Niche Oncology Drug? Investors Are Excited!
About Immunitybio Inc
CEORich Adcock
Employees688
Founded2014
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteimmunitybio.com